{
  "abstract": "Background: Clinical trials showed a non-inferior efficacy of lenvatinib versus sorafenib as first- or second-line treatment for advanced hepatocellular carcinoma (HCC). However, comparative effectiveness has not been definitively established. Our study aimed to compare the effectiveness of lenvatinib versus sorafenib as first-line therapy for advanced HCC in a real-world cohort and to integrate these findings with the available current evidence on the use of both drugs as first- or second-line therapy.\n\nMethods: We conducted a propensity score-matched analysis including patients who were treated with lenvatinib or sorafenib as first-line therapy between January 2020 and December 2024. We also performed a systematic review and meta-analysis comparing the effectiveness of lenvatinib versus sorafenib as first-line therapy and a systematic review investigating the effectiveness of tyrosine-kinase inhibitor (TKI) as second-line therapy for advanced HCC.\n\nResults: In our matched cohort (n = 84 patients), the patients treated with lenvatinib showed longer median overall survival than those treated with sorafenib (17.7 vs 11.2 months; P = 0.224). A meta-analysis of lenvatinib versus sorafenib as first-line therapy (n = 3,549 patients) demonstrated better outcomes for lenvatinib than for sorafenib in terms of overall survival, objective response rate, and disease control rate. In a proportional meta-analysis, lenvatinib showed a significantly higher objective response rate (38% vs 9%; P < 0.001) and a higher partial response rate (36% vs 9%; P < 0.001) than sorafenib. Results from the systematic review for TKI as second-line strategy (n = 1,011 patients) showed a trend toward better outcomes with lenvatinib, although limited data are available.\n\nConclusions: In the first-line setting, patients treated with lenvatinib had better clinical responses than did those treated with sorafenib. For second-line treatment, evidence is limited; however, available data show a trend toward better outcomes with lenvatinib and prospective studies are needed to confirm these findings.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "Rosanna Villani",
      "orcid": "0000-0001-9875-019X"
    },
    {
      "name": "Elisabetta Cornacchia"
    },
    {
      "name": "Nicolò Maria Sguera"
    },
    {
      "name": "Tommaso Colangelo"
    },
    {
      "name": "Tommaso Cassano"
    },
    {
      "name": "Danilo Di Bona"
    },
    {
      "name": "Gaetano Serviddio"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c6v92tqvhhxbq.bib",
  "cited_by": 0,
  "doi": "10.1093/gastro/goag109",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13713194/",
  "id": "c6v92tqvhhxbq",
  "issns": [
    "2052-0034"
  ],
  "landing_url": "https://doi.org/10.1093/gastro/goag109",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00260"
    ],
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7223943596",
  "pdf_url": "https://academic.oup.com/gastro/article-pdf/doi/10.1093/gastro/goag109/72543893/goag109.pdf",
  "pmcid": "PMC13713194",
  "pmid": "42948847",
  "published": "2026-10-27",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/c6v92tqvhhxbq.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:23:35Z",
      "native_id": "PMC13713194",
      "source": "pmc",
      "url": "https://doi.org/10.1093/gastro/goag109"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Effectiveness of lenvatinib versus sorafenib as first- or second-line therapy in hepatocellular carcinoma: insights from real-life data, systematic review, and meta-analysis",
  "title_text": "Effectiveness of lenvatinib versus sorafenib as first- or second-line therapy in hepatocellular carcinoma: insights from real-life data, systematic review, and meta-analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:23:35Z",
  "url": "https://research.draconitic.com/paper/c6v92tqvhhxbq",
  "venue": "Gastroenterology Report",
  "versions": []
}